We are committed to improving the lives of people suffering from traumatic injuries and degenerative disease. We aim to do this in partnership; by listening to patients, supporters and advocacy communities and hearing your stories. It is your words and your resilience that motivate us to advance the understanding of rare disease and work to deliver new treatments to as many patients as possible.
Allegro is currently concluding pre-clinical trials on its lead asset in osteoarthritis.
Allegro has opened a clinical trial in Belgium (NCT07516457) in 2026 to assess its lead hydrogel, Hydrocelin, in patients with knee osteoarthritis. For more information please visit ClinicalTrials.gov
If you are interested in participating in an Allegro clinical trial or would like more information, or if you have any questions about the trial, please talk to your doctor. Allegro is unable to respond to specific enquiries about our clinical trials and encourages you to discuss your case directly with your doctor or the clinical trial site, rather than the company.